Bavarian Nordic A/S (BVNKF)
PNK: BVNKF
· Real-Time Price · USD
23.08
0.00 (0.00%)
At close: Apr 28, 2025, 9:30 AM
0.00% (1D)
| Bid | 22.8 |
| Market Cap | 1.81B |
| Revenue (ttm) | 5.72B |
| Net Income (ttm) | 987.98M |
| EPS (ttm) | 1.92 |
| PE Ratio (ttm) | 12.02 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 25 |
| Volume | 100 |
| Avg. Volume (20D) | 296 |
| Open | 23.00 |
| Previous Close | 23.08 |
| Day's Range | 23.00 - 23.08 |
| 52-Week Range | 18.72 - 46.05 |
| Beta | 1.38 |
About BVNKF
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials fo...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 15, 2010
Employees 1,605
Stock Exchange PNK
Ticker Symbol BVNKF
Website https://www.bavarian-nordic.com
3 weeks ago · seekingalpha.com
Bavarian Nordic Trading At Great Value Levels With Upbeat 2025 OutlookBVNKF now expects margin improvements from rabies/TBE vaccine production transfers to Denmark, starting in 2025. Also, their recently FDA-approved freeze-dried Jynneos vaccine and EU/US-approved chiku...
